Heparin-induced thrombocytopenia

Visão geral 
Teoria 
Diagnóstico 
Tratamento 
ACOMPANHAMENTO 
Recursos 

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Última revisão: 20 Aug 2025

Última atualização: 20 Jun 2023

Heparin-induced thrombocytopenia (HIT) is a severe drug reaction to heparin that can lead to life- and limb-threatening venous and/or arterial thromboembolism.

Diagnosis requires the combination of a compatible clinical picture and laboratory confirmation of the presence of heparin-dependent platelet-activating HIT antibodies.

The 4Ts score is commonly used to determine the clinical probability of HIT.

Neither discontinuation of heparin alone nor initiation of a vitamin K antagonist alone (e.g., warfarin) is sufficient to stop the development of thrombosis in a patient with acute HIT.

If a patient has suspected HIT and at least an intermediate-probability 4Ts score, all sources of heparin (including low molecular weight heparin) must be discontinued and a nonheparin anticoagulant should be initiated.

Definición

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic syndrome that occurs when heparin-dependent, IgG antibodies bind to heparin/platelet factor 4 (PF4) complexes to activate platelets and produce a hypercoagulable state. This results in thrombocytopenia and/or thrombosis in temporal relationship to a preceding immunizing exposure to heparin.[1] HIT typically develops 5 to 10 days after exposure to heparin (range of 4-15 days) and can occur with unfractionated heparin, low molecular weight heparin, or, more rarely, fondaparinux. The presence of heparin-dependent antibodies alone, without any clinical manifestations, is insufficient for a diagnosis of HIT.

Fondaparinux, a pentasaccharide anticoagulant, does not usually promote antibody binding to PF4, despite its structural similarity to heparin, owing to absent/weak cross-reactivity. Therefore, it has a very low risk of inducing HIT. Despite rare reports of fondaparinux-induced HIT, observational studies report the successful use of fondaparinux to treat HIT, and it is considered to be a nonheparin anticoagulant.[2][3]

Anamnesis y examen

Principales factores de diagnóstico

history of recent heparin exposure
history of HIT
absence of conditions and medications that cause thrombocytopenia
history of recent surgery or trauma
features consistent with recent venous or arterial thromboembolic event (e.g., PE, DVT, stroke, MI)
necrosis at heparin injection site(s)

Todos los datos

Otros factores de diagnóstico

absence of bleeding
signs of adrenal hemorrhagic necrosis
acute systemic reaction
signs of venous limb gangrene

Todos los datos

Factores de riesgo

recent heparin exposure (within past 100 days)
recent orthopedic or cardiovascular surgery
female sex

Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

Todos los datos

Pruebas diagnósticas que deben considerarse

4Ts score
HIT antigen assay
HIT functional assay
coagulation studies
venous Doppler ultrasound
computed tomography pulmonary angiogram (CTPA)
ventilation-perfusion scan (V/Q scan)
cerebral computed tomography venogram
magnetic resonance venography (head)

Todos los datos

Algoritmo de tratamiento

Agudo

suspected HIT with 4Ts score ≥4, or confirmed acute HIT

suspected HIT with 4Ts score ≤3

En curso

platelet recovery (subacute HIT A)

remote HIT

Colaboradores

Autores

Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC

Associate Professor

Department of Medicine

McMaster University

Thrombosis Consultant

Juravinski Hospital and Cancer Centre

Hamilton

Ontario

Canada

Divulgaciones

LL is an author of several references cited in this topic.

Revisores por pares

Jeffrey S. Wasser, MD

Assistant Clinical Professor of Medicine

Acting Associate Chair of the Division of Hematology and Medical Oncology

University of Connecticut School of Medicine

Farmington

Divulgaciones

JSW declares that he has no competing interests.

Henry Watson, MD, FRCP, FRCPath

Consultant Haematologist

Aberdeen Royal Infirmary

Foresterhill Health Campus

Aberdeen

Divulgaciones

HW declares that he has no competing interests.

Simon Davidson, MPhil

Clinical Scientist

Royal Brompton Hospital

Honorary Clinical Lecturer

Imperial College London

London

Divulgaciones

SD is a consultant for Mitsubishi Pharma, the manufacturer of argatroban.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Warkentin T, Kelton J. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.Texto completo Resumen

Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-92.Texto completo Resumen

Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis (9th ed). American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e495S-e530S.Texto completo Resumen

Watson H, Davidson S, Keeling D, et al. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012 Dec;159(5):528-40.Texto completo Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Diferenciales
- Postoperative state
- Thrombotic thrombocytopenic purpura
- Drug-induced thrombocytopenic purpura
Más Diferenciales
Guías de práctica clínica
- Guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
- Treatment and prevention of heparin-induced thrombocytopenia
Más Guías de práctica clínica
Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad

Heparin-induced thrombocytopenia

Resumo

Definición

Anamnesis y examen

Principales factores de diagnóstico

Otros factores de diagnóstico

Factores de riesgo

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

Pruebas diagnósticas que deben considerarse

Algoritmo de tratamiento

suspected HIT with 4Ts score ≥4, or confirmed acute HIT

suspected HIT with 4Ts score ≤3

platelet recovery (subacute HIT A)

remote HIT

Colaboradores

Autores

Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC

Divulgaciones

Revisores por pares

Jeffrey S. Wasser, MD

Divulgaciones

Henry Watson, MD, FRCP, FRCPath

Divulgaciones

Simon Davidson, MPhil

Divulgaciones

Peer reviewer acknowledgements

Disclosures

Referencias

Artículos principales

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Diferenciales

Guías de práctica clínica

Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice

Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice

Inicie sesión para acceder a todo el BMJ Best Practice